Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ampio Pharmaceuticals (AMPE)
OTHER OTC:AMPE
Ampio Pharmaceuticals (AMPE) Stock Price & Analysis
511 Followers
AMPE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.14 - $8.28
Previous Close$0.29
Volume385.00
Average Volume (3M)69.13K
Market Cap
$363.32K
Enterprise Value-$3.50M
Total Cash (Recent Filing)$4.10M
Total Debt (Recent Filing)$274.00K
Price to Earnings (P/E)>-0.1
Beta1.22
Next Earnings
May 09, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.09
Shares Outstanding1,135,358
10 Day Avg. Volume50,155
30 Day Avg. Volume69,130
Standard Deviation0.32
R-Squared0.10
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.21
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ampio Pharmaceuticals News
PremiumCompany Announcements
Ampio Pharmaceuticals Ends Equity Distribution and Alters Strategy
PremiumCompany Announcements
Ampio Pharmaceuticals Announces Nonclinical Study Success
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMPE FAQ
What was Ampio Pharmaceuticals’s price range in the past 12 months?
Ampio Pharmaceuticals lowest stock price was $0.14 and its highest was $8.28 in the past 12 months.
What is Ampio Pharmaceuticals’s market cap?
Currently, no data Available
When is Ampio Pharmaceuticals’s upcoming earnings report date?
Ampio Pharmaceuticals’s upcoming earnings report date is May 09, 2024 which is in 15 days.
How were Ampio Pharmaceuticals’s earnings last quarter?
Ampio Pharmaceuticals released its earnings results on May 11, 2023. The company reported -$0.264 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.264.
Is Ampio Pharmaceuticals overvalued?
According to Wall Street analysts Ampio Pharmaceuticals’s price is currently Overvalued.
Does Ampio Pharmaceuticals pay dividends?
Ampio Pharmaceuticals does not currently pay dividends.
What is Ampio Pharmaceuticals’s EPS estimate?
Ampio Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ampio Pharmaceuticals have?
Ampio Pharmaceuticals has 1,135,358 shares outstanding.
What happened to Ampio Pharmaceuticals’s price movement after its last earnings report?
Ampio Pharmaceuticals reported an EPS of -$0.264 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 23.515%.
Which hedge fund is a major shareholder of Ampio Pharmaceuticals?
Among the largest hedge funds holding Ampio Pharmaceuticals’s share is Sheaff Brock Investment Advisors LLC. It holds Ampio Pharmaceuticals’s shares valued at N/A.
---
Ampio Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AMPE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 57.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.41%
12-Months-Change
Fundamentals
Return on Equity
-113.96%
Trailing 12-Months
Asset Growth
-57.79%
Trailing 12-Months
Company Description
Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation, and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in April 2010 and is headquartered in Englewood, CO.
---
Technical Analysis
---